# Hepcludex注射劑用於治療無肝硬化成人慢性丙型肝炎病毒感染。

*biotech · news · 2026-05-22 · Markets Insider*

## Key points

- FDA已核准Hepcludex（bulevirtide）用於治療成人慢性丙型肝炎病毒感染。
- Bulevirtide是FDA首個專門核准用於慢性HDV感染的治療藥物。
- Hepcludex獲准用於有無代償性肝硬化的成人慢性HDV患者。
- 在此核准之前，尚無FDA核准的慢性丙型肝炎病毒感染治療方案。
- FDA的核准授予Gilead Sciences, Inc.。

The U.S. Food and Drug Administration approved Hepcludex injection to treat chronic hepatitis delta virus infection in adults without cirrhosis or with compensated cirrhosis. Bulevirtide is the first FDA-approved treatment for chronic HDV infection, a serious and life-threatening condition that can cause rapid development of liver fibrosis, liver cancer, liver failure, and even death. “Today’s approval fills a critical gap in care for patients with chronic HDV infection, who until now have had no FDA-approved therapies available,” said Wendy Carter, D.O., Acting Director of the Office of Infectious Diseases in FDA’s Center for Drug Evaluation and Research. “For individuals living with this chronic viral infection, this new treatment option offers hope in managing a disease that can rapidly progress to serious liver complications.” The FDA granted the approval to Gilead (GILD) Sciences, Inc. Meet Samuel – Your Personal Investing Prophet

**Companies:** Gilead Sciences, Inc.
**Countries:** United States

[Read the full story on Markets Insider](https://markets.businessinsider.com/news/stocks/fda-approves-gilead-s-hepcludex-injection-to-treat-chronic-hdv-infection-1036189734)

---

Canonical: https://newsio.io/zh-TW/n/8b42a86e-9aeb-43ca-95d6-84eea08d1236/hepcludexbulevirtidefdahdv
Summarized by Newsio from Markets Insider. https://newsio.io/how-it-works